Industry News-Applitech Pharmaceutical Equipment Technology Co.Ltd

2010 global biopharmaceutical industry, total R & D costs amounted to $ 67,410,000,000, of which R & D investment in the top 10 pharmaceutical companies in more than 10% of total investment.

High R & D investment in recent years, major drug patent expires, industry mergers and acquisitions and other factors. Among them, the Pfizer R & D through the structural adjustment of drug R & D investment of 94 billion U.S. dollars, ranking the first place.

Pfizer plans previously cut R & D investment in 2012 to 80 billion to $ 8.5 billion, recently decided to 65 billion to 70 billion dollars. Mainly related to municipal governance in the UK Sangwei R & D center and Groton, Conn., urinary global R & D center, the field of allergy and RNAi 1000 R & D jobs. Pfizer will strengthen in Boston, Cambridge, UK and San Francisco R & D capability, increase and CRO companies.

Pfizer’s drug, including the existing high hopes for the end of the year expected to be granted non-small cell lung cancer drug crizotinib, kidney cancer drug axitinib and chronic myeloid leukemia drug bosutinib.

Nearly $ 47 billion acquisition of Roche’s Genentech, after winning the world’s most innovative large-scale biopharmaceutical company honor, but there is no such as Pfizer and other pharmaceutical patent expiration issues.

Roche cut RNAi5 billion R & D investment. Late last year, Roche, respectively, in hepatitis C with Ligand Transgene Company terminated the project and cooperation agreement, also announced cut 600 R & D personnel. Like with Pfizer and Novartis, Roche plans to increase R & D investment in China. China, as Asia’s largest pharmaceutical market will provide new opportunities.

When ready to cut R & D budget, Pfizer, Merck but then a soft spot for drug development. Merck acquired Schering-Plough, the company’s R & D investment increased sharply to 80 billion U.S. dollars.

Merck’s R & D investment in 2009 reached $ 5.6 billion, but the company has suffered setbacks, failures due to loss of anticoagulant Vorapaxar $ 1.7 billion. By year-end return to oral HCV protease inhibitor boceprevir rapid approval by the United States and the European Union, is expected for the treatment of chronic hepatitis C; cholesterol ester transfer protein (CETP) inhibitors, low-density lipoprotein cholesterol drugs can anacetrapib (LDL) reduced by 40%, very "blockbuster" level potential;

Late last year, for $ 500 million acquisition of Merck diabetes drug developer SmartCells. Merck plans to fight the company’s major pharmaceutical companies in the biosimilars leader.

Novartis R & D investment in 2010 increased by 10%, in Merck after. With the decline in Pfizer R & D investment, Novartis will enter the global biopharmaceutical R & D investment in the top three.

Late last year, Novartis plans to recruit 200 to 300 researchers, so that in the U.S. research base in Cambridge, Massachusetts, who doubled, the company will spend $ 600 million for this.

Novartis R & D strategies tend to rely on internal research, instead of chasing other large companies that have a higher risk of bio-technology company’s new products. In addition, the company attaches great importance to individual drug, and those who treat small patient populations with a variety of diseases indications of drug development.

Novartis currently has 147 clinical development program, including the most talked about late rare disease drugs - the treatment of Cushing’s syndrome, drug SOM230 (pasireotide).

NO.5 Johnson

$ 6,840,000,000

Last year, Johnson’s treatment of prostate cancer drug A Bite Dragon (Abiraterone) in late-stage clinical trials performed well, which leads to the U.S. and European markets for its foundation. In January, Bayer and Johnson & Johnson filed a joint new once-daily oral anti-clotting drug Xarelto (rivaroxaban) a new drug application. Analysts expect the annual volume of Xarelto will reach $ 3 billion.

Johnson’s hepatitis C protease inhibitor TMC435 has now entered Phase Ⅲ study stage. In addition, anti-diabetic drug Canagliflozin SGLT2 10,000 patients currently is conducting Phase Ⅲ study.

NO.6 GlaxoSmithKline

$ 6,090,000,000

From 1998 to 2007, GlaxoSmithKline invested over $ 3 billion annually, but did not get a new molecular entity. The face of investor criticism, hundreds of British companies to cut staff and sell at a research center in Verona, Italy, as a response.

Currently, GSK’s growing interest in the field of rare disease drugs. Companies in emerging markets and increase investment in the field of vaccines, while reducing acquisition efforts, the 2010 acquisition of investment of 3.54 billion euros, well below the 2009 to 28 billion euros. In 2010, GlaxoSmithKline R & D investment increased slightly compared with 2009 (8%), R & D investment this year is expected to grow 14%.

Recently, GlaxoSmithKline and the U.S. Human Genome Sciences, jointly developed lupus drug Benlysta received FDA clearance to market, this is the first time in nearly 56 years of lupus drug approval, estimated Benlysta annual sales of $ 5.0 billion. GlaxoSmithKline has the European Union, Canada, Australia, Switzerland and Russia submitted a listing application, before the end of this year plans to submit applications to more countries.

NO.7 Sanofi-Aventis

$ 5,940,000,000

Sanofi-Aventis R & D strategy to re-adjust in acquisitions frequently generous. Last summer, Sanofi for $ 560 million acquisition of U.S. biotechnology company TargeGen company, involved in malignant blood disease research. Back in 2009, Sanofi for $ 500 million acquisition of a California biotechnology company BiParSciences to gain a mid-stage anti-cancer drug iniparib, currently in Phase Ⅲ stage. Earlier this year, Sanofi to over 20.1 billion U.S. dollars to buy Genzyme, so as to enter the field of rare disease drugs to raise the stakes. Sanofi after a lot of acquisitions, while also attaches great importance to cooperation with academic institutions, and actively explore new markets.

As of February this year, Sanofi has 55 clinical development programs, 13 stage Ⅲ or approved application for the project need to be outsourced.

NO.8 AstraZeneca

$ 5,300,000,000

Following last year’s tanezumab Pfizer and Johnson & Johnson’s fulranumab two nerve growth factor inhibitor painkillers to stop the study due to side effects after AstraZeneca took the initiative to stop the nerve growth factor inhibitors medi578 research. Analysts believe that nerve growth factor inhibitor class of drugs in the market at an average of about $ 11 billion.

In addition, continued with AstraZeneca suffered a respiratory antiviral motavizumab, prostate and colon cancer drugs zibotentan drugs Recentin Phase Ⅲ failure. ,

Last year, AstraZeneca drug Brilinta antiplatelet therapy by the U.S. FDA to postpone approval.

NO.9 Lilly

$ 4,880,000,000

2010 Lilly drug R & D investment of nearly 50 billion U.S. dollars, an increase of 13% in 2009. Lilly said this year will be invested to maintain a high growth rate.

In August last year, Lilly’s Alzheimer’s disease drugs can slow the disease because they do not semagacestat progress and worsen the patient’s condition also appeared to fail. Today, Lilly to focus more on diabetes drugs Bydureon, the FDA last fall asked Lilly to add Bydureon the research data on the QT.

Although Lilly repeated failures in drug development, but there are still a number of late-stage companies or projects to be assessed.

NO.10 Bristol-Myers Squibb

$ 3,560,000,000

Last year, Bristol-Myers Squibb R & D investment accounted for 18.3% of revenue, expected R & D expenses will also increase.

Bristol-Myers Squibb in a variety of new drugs developed last year in the late stages, including skin cancer very promising drugs ipilimumab, cancer drugs XL-184, and the diabetes drug dapagliflozin anticoagulant apixaban. In addition, Bristol-Myers Squibb has three drugs Sprycel, Orencia and Onglyza approved expanded indications. 2012 Bristol-Myers Squibb in the late stages of product research there will be five approved listing.

(Bio Valley Bioon.com)